Home > Healthcare > Pharmaceuticals > Finished Drug Form > Alexipharmic Drugs Market

Alexipharmic Drugs Market Size

Report ID: GMI8415
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Alexipharmic Drugs Market Size

Alexipharmic Drugs Market size was valued at around USD 3.2 billion in 2023 and is estimated to grow at a CAGR of 4.8% between 2024 and 2032. This robust market growth can be attributed to factors such as the growing usage of psychoactive substances narcotic drugs coupled with the increasing awareness regarding preventive poisoning.

To get key market trends

Download Free Sample

The surge in substance abuse poses unprecedented challenges to public health, necessitating effective interventions to counteract the adverse effects of these substances. Widespread opioid use disorder has led to a surge in overdose incidents around the globe. According to the Penington Institute, the estimated number of people using opioids globally doubled from 26-36 million people in 2010 to 61.3 million in 2020.

Alexipharmic drugs, particularly opioid antagonists like naloxone, are essential in reversing the life-threatening respiratory depression caused by opioid overdoses. The urgent need for these antidotes has significantly contributed to the growth of the market. Alexipharmic drugs, also known as antidotes, are pharmaceutical agents that counteract the effects of toxins, poisons, or harmful substances in the body. The use of these drugs is essential in emergency medical situations where rapid intervention is required to prevent or mitigate the harmful consequences of poisoning.

Alexipharmic Drugs Market Report Attributes
Report Attribute	Details
Base Year:	2023
Alexipharmic Drugs Market Size in 2023:	USD 3.2 Billion
Forecast Period:	2024 to 2032
Forecast Period 2024 to 2032 CAGR:	4.8%
2032 Value Projection:	USD 4.8 Billion
Historical Data for:	2018 – 2023
No. of Pages:	180
Tables, Charts & Figures:	306
Segments covered:	Application, Route of Administration, Distribution Channel, End-use, and Region
Growth Drivers:	Growing usage of psychoactive substances and narcotic drugs Rising expenditure on the R&D of novel treatments Increase in awareness regarding preventive poisoning
Pitfalls & Challenges:	Complications and adverse drug events related to medications

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Alexipharmic drugs market size was USD 3.2 billion in 2023 and is expected to register 4.8% CAGR from 2024-2032 owing to the growing usage of psychoactive substances narcotic drugs coupled with the increasing awareness regarding preventive poisoning worldwide.

Alexipharmic drugs industry from the opioid overdose segment crossed USD 1.1 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to governments and regulatory bodies increasingly recognizing the severity of the opioid crisis.

North America alexipharmic drugs industry reached USD 1.3 billion in 2023 and is expected to register a commendable CAGR from 2024-2032 due to the presence of a robust healthcare infrastructure and extensive research & development initiatives in the region.

AdvaCare Pharma, American Regent, Inc., B. Braun Melsungen AG, Bausch Health Companies Inc, Fresenius SE & Co. KGaA, Intelicure Lifesciences, Merck KGaA, Mylan N.V., and SimSon Pharma Limited, are some of the major alexipharmic drugs companies worldwide.